Who are Aspirin or thienopyridine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Blinded clopidogrel, placebo, aspirine, clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-or-thienopyridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aspirin or thienopyridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aspirin or thienopyridine (Aspirin or thienopyridine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agents. Area: Cardiovascular.

marketed Antiplatelet agents COX-1 (aspirin); P2Y12 receptor (thienopyridines) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin or thienopyridine (Aspirin or thienopyridine) — Associations for Establishment of Evidence in Interventions. Aspirin and thienopyridines inhibit platelet aggregation through different pathways to prevent blood clots and reduce cardiovascular events.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aspirin or thienopyridine TARGET	Aspirin or thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Antiplatelet agents	COX-1 (aspirin); P2Y12 receptor (thienopyridines)
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
placebo, aspirine, clopidogrel	placebo, aspirine, clopidogrel	University Hospital, Angers	marketed	Antiplatelet agents	Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agents class)

Associations for Establishment of Evidence in Interventions · 1 drug in this class
University Hospital, Angers · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin or thienopyridine — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-or-thienopyridine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab